A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) predicts a poor prognosis. The aim of the present study was to evaluate the efficacy and safety of using lenvatinib and camrelizumab combined with transarterial chemoembolization (TACE) to treat HCC with PVTT....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomi, Ding, Xiaoyan, Liu, Mei, Wang, Jingyan, Sun, Wei, Teng, Ying, Xu, Yawen, Wu, Hongxiao, Li, Wendong, Zhou, Lin, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501288/
https://www.ncbi.nlm.nih.gov/pubmed/37387602
http://dx.doi.org/10.1002/cam4.6302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501288/
https://www.ncbi.nlm.nih.gov/pubmed/37387602
http://dx.doi.org/10.1002/cam4.6302

Ejemplares similares